[go: up one dir, main page]

ECSP11005768A - Derivados de azol-pirimidina condensados - Google Patents

Derivados de azol-pirimidina condensados

Info

Publication number
ECSP11005768A
ECSP11005768A EC2011005768A ECSP11005768A ECSP11005768A EC SP11005768 A ECSP11005768 A EC SP11005768A EC 2011005768 A EC2011005768 A EC 2011005768A EC SP11005768 A ECSP11005768 A EC SP11005768A EC SP11005768 A ECSP11005768 A EC SP11005768A
Authority
EC
Ecuador
Prior art keywords
condensed
azol
pyrimidine derivatives
derivatives
azolpyrimidine
Prior art date
Application number
EC2011005768A
Other languages
English (en)
Inventor
Mitsuyuki Shimada
Toshiki Murata
Hideki Tsujishita
Naoki Omori
Issei Kato
Mami Miura
Klaus Urbahns
Florian Gantner
Kevin Bacon
Kinji Fuchikama
Original Assignee
Bayer Schering Pharma A G
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma A G filed Critical Bayer Schering Pharma A G
Publication of ECSP11005768A publication Critical patent/ECSP11005768A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a nuevos derivados de azolpirimidina condensados, a procedimientos para su preparación y a preparaciones farmacéuticas que los contienen. Los derivados de azolpirimidina condensados de la presente invención presentan una mayor potencia para la inhibición de la fosfatidilinositol-3-quinasa (PI3K), especialmente para la inhibición de la PI3K- .
EC2011005768A 2002-09-30 2011-02-07 Derivados de azol-pirimidina condensados ECSP11005768A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02021861 2002-09-30

Publications (1)

Publication Number Publication Date
ECSP11005768A true ECSP11005768A (es) 2011-03-31

Family

ID=32039115

Family Applications (2)

Application Number Title Priority Date Filing Date
EC2005005768A ECSP055768A (es) 2002-09-30 2005-04-28 Derivados de azol-pirimidina condensados
EC2011005768A ECSP11005768A (es) 2002-09-30 2011-02-07 Derivados de azol-pirimidina condensados

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EC2005005768A ECSP055768A (es) 2002-09-30 2005-04-28 Derivados de azol-pirimidina condensados

Country Status (32)

Country Link
US (2) US7511041B2 (es)
EP (2) EP1549652B1 (es)
JP (1) JP4790266B2 (es)
KR (1) KR101059652B1 (es)
CN (1) CN100384846C (es)
AR (2) AR041426A1 (es)
AT (2) ATE411996T1 (es)
AU (1) AU2003293310B2 (es)
BR (1) BRPI0314830B8 (es)
CA (1) CA2499134C (es)
CY (2) CY1109790T1 (es)
DE (1) DE60324296D1 (es)
DK (2) DK1549652T3 (es)
EC (2) ECSP055768A (es)
ES (2) ES2367141T3 (es)
HR (2) HRP20131159B1 (es)
IL (1) IL166855A (es)
MA (1) MA27483A1 (es)
MX (1) MXPA05001808A (es)
MY (1) MY140756A (es)
NO (1) NO331457B1 (es)
NZ (1) NZ539062A (es)
PE (1) PE20050089A1 (es)
PL (1) PL226562B1 (es)
PT (2) PT1549652E (es)
RU (1) RU2326881C9 (es)
SI (2) SI2042504T1 (es)
TW (1) TWI327570B (es)
UA (1) UA82205C2 (es)
UY (1) UY28001A1 (es)
WO (1) WO2004029055A1 (es)
ZA (1) ZA200503306B (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
CN100554249C (zh) 2003-08-29 2009-10-28 三井化学株式会社 农园艺用杀虫剂及其使用方法
PT2612862T (pt) 2004-05-13 2016-12-15 Icos Corp Quinazolinonas como inibidores de fosfatidilinositol 3-quinase delta humana
RU2403258C2 (ru) 2004-10-07 2010-11-10 Бёрингер Ингельхайм Интернациональ Гмбх Тиазолилдигидроиндазолы
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
AU2006236621B2 (en) 2005-04-14 2011-10-06 The Trustees Of Boston University Diagnostic for lung disorders using class prediction
WO2007016979A2 (en) * 2005-07-29 2007-02-15 4Sc Ag NOVEL HETEROCYCLIC NF-κB INHIBITORS
EP1999472A2 (en) 2006-03-09 2008-12-10 The Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US7517995B2 (en) * 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
PL2041139T3 (pl) * 2006-04-26 2012-05-31 Hoffmann La Roche Związki farmaceutyczne
WO2008064244A2 (en) * 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP1953163A1 (en) * 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinone derivatives as PI3-kinases inhibitors
WO2008148023A2 (en) * 2007-05-23 2008-12-04 Medical College Of Georgia Research Institute, Inc. Compositions and methods for treating neurological disorders
US20100204222A1 (en) * 2007-09-17 2010-08-12 GlaxoSmithKline, LLC Pyridopyrimidine derivatives as p13 kinase inhibitors
JP2010538680A (ja) * 2007-09-19 2010-12-16 ザ トラスティーズ オブ ボストン ユニバーシティー 肺疾患に対する薬剤開発のための新規経路の同定
WO2009091550A2 (en) * 2008-01-14 2009-07-23 Bayer Healthcare Llc Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
EP2250160B1 (en) 2008-01-25 2015-11-11 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
US20090227575A1 (en) * 2008-03-04 2009-09-10 Wyeth 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
US20110105457A1 (en) * 2008-04-18 2011-05-05 Shionogi & Co., Ltd. Heterocyclic compound having inhibitory activity on pi3k
EP2303890A4 (en) * 2008-06-19 2012-04-11 Progenics Pharm Inc INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE
EP2168582A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
CA2735932C (en) * 2008-09-30 2013-07-09 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
PL2364983T3 (pl) * 2008-11-11 2014-04-30 Jeil Pharmaceutical Co Ltd Nowa pochodna tricykliczna lub jej farmaceutycznie dopuszczalne sole, sposób jej wytwarzania, oraz zawierająca ją kompozycja farmaceutyczna
WO2010057048A1 (en) 2008-11-13 2010-05-20 Calistoga Pharmaceuticals Inc. Therapies for hematologic malignancies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MX2011009955A (es) 2009-03-24 2011-11-18 Gilead Calistoga Llc Atropisomeros de derivados de 2-purinil-3-tolil-quinazolinona y metodos de uso.
AP2011005956A0 (en) 2009-04-20 2011-10-31 Gilead Calistoga Llc Methods of treatment for solid tumors.
ES2876933T3 (es) * 2009-04-30 2021-11-15 Glaxo Group Ltd Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas
US8669057B2 (en) 2009-05-07 2014-03-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
AU2010276160A1 (en) 2009-07-21 2012-02-09 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
US20110230476A1 (en) * 2009-09-09 2011-09-22 Avila Therapeutics, Inc. Pi3 kinase inhibitors and uses thereof
CA2796253A1 (en) 2010-04-16 2011-10-20 Bayer Intellectual Property Gmbh Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AU2011310532B2 (en) 2010-10-01 2016-01-14 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
CA2817287A1 (en) 2010-11-11 2012-05-18 Bayer Intellectual Property Gmbh Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
CA2817312A1 (en) 2010-11-11 2012-05-18 Bayer Intellectual Property Gmbh Alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
MD20140100A2 (ro) 2012-03-05 2015-01-31 Gilead Calistoga Llc Forme polimorfe ale (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilchinazolin-4(3H)-onei
EP2968988A4 (en) 2013-03-14 2016-11-16 Allegro Diagnostics Corp METHOD FOR EVALUATING A COPD STATUS
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
WO2014144850A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
UA119537C2 (uk) 2013-04-08 2019-07-10 Байєр Фарма Акцієнгезелльшафт ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ
PE20161063A1 (es) 2013-05-01 2016-10-22 Hoffmann La Roche Compuestos de biheteroarilo y usos de los mismos
WO2015027431A1 (en) * 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
US9567337B2 (en) 2013-12-20 2017-02-14 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
WO2015191726A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018131A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
CN107864625B (zh) 2015-03-09 2021-05-28 拜耳制药股份公司 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法
CN105130997B (zh) * 2015-09-25 2017-12-05 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
CA3016584A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
CN109729716B (zh) 2016-09-23 2022-03-15 拜耳制药股份公司 Pi3k-抑制剂的组合产品
CA3045041A1 (en) 2016-12-14 2018-06-21 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
EP3585437B1 (en) 2017-02-24 2022-12-21 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-pd-1 antibody
EP3645005A1 (en) 2017-06-28 2020-05-06 Bayer Consumer Care AG Combination of a pi3k-inhibitor with an androgen receptor antagonist
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
PE20200958A1 (es) 2017-09-08 2020-09-24 Bayer Consumer Care Ag Solido liofilizado de copanlisib
EP3684772B1 (en) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
WO2019073031A1 (en) 2017-10-13 2019-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) POLYTHERAPY OF PANCREATIC CANCER
WO2019101871A1 (en) 2017-11-23 2019-05-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) A new marker for predicting the sensitivity to pi3k inhibitors
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
CN112789279B (zh) * 2018-07-27 2023-09-29 上海翰森生物医药科技有限公司 含三并环类衍生物抑制剂、其制备方法和应用
CN109053554B (zh) * 2018-08-01 2020-07-28 江苏八巨药业有限公司 一种使用催化剂合成3-乙酰吡啶的方法
EP3843743A1 (en) 2018-08-28 2021-07-07 Bayer AS Combination of pi3k-inhibitors and targeted thorium conjugates
EP3866805A1 (en) 2018-10-16 2021-08-25 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
CN114621236B (zh) * 2022-04-25 2024-06-18 河南湾流生物科技有限公司 一种喹啉类饲料添加剂的制备方法
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644354A (en) * 1968-09-16 1972-02-22 Sandoz Ag 5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines
US4287341A (en) 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
NZ234186A (en) * 1989-07-07 1991-10-25 Janssen Pharmaceutica Nv Imidazo quinazolin-one derivatives and pharmaceutical compositions
CN1033644C (zh) * 1993-01-02 1996-12-25 瑞安大药厂股份有限公司 3-取代甲基-2，3-二氢咪唑并[1，2-c]喹唑啉衍生物，其制备与用途
EP0771204A4 (en) 1994-08-12 1999-10-20 Pro Neuron Inc METHOD FOR TREATING SEPSIS OR FLAMMABLE DISEASES WITH OXYPURINE NUCLEOSIDES
EP0885192B8 (en) * 1996-01-29 2012-05-16 The United States of America, Represented by the Secretary, Department of Health and Human Services Dihydropyridine-, pyridine-, benzopyran- one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists
US5932584A (en) * 1997-05-06 1999-08-03 National Science Council Optically active 2,3-dihydroimidazo(1,2-C) quinazoline derivatives, the preparation and antihypertensive use thereof
ATE502941T1 (de) 2000-04-25 2011-04-15 Icos Corp Hemmer der menschlichen phosphatidyl-inositol-3- kinase delta
KR100774855B1 (ko) * 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체

Also Published As

Publication number Publication date
KR101059652B1 (ko) 2011-08-25
US8129386B2 (en) 2012-03-06
RU2326881C2 (ru) 2008-06-20
PT1549652E (pt) 2008-12-15
HRP20131159A2 (hr) 2014-05-23
TW200413379A (en) 2004-08-01
CN100384846C (zh) 2008-04-30
ATE411996T1 (de) 2008-11-15
HRP20050375A2 (en) 2006-05-31
WO2004029055A1 (en) 2004-04-08
US7511041B2 (en) 2009-03-31
PT2042504E (pt) 2011-09-07
CY1109790T1 (el) 2014-09-10
HRP20131159B1 (hr) 2019-11-01
TWI327570B (en) 2010-07-21
SI1549652T1 (sl) 2009-04-30
AR072458A2 (es) 2010-09-01
UY28001A1 (es) 2004-04-30
AU2003293310A1 (en) 2004-04-19
PL375935A1 (en) 2005-12-12
ES2312843T3 (es) 2009-03-01
DE60324296D1 (de) 2008-12-04
NO20052076L (no) 2005-04-27
UA82205C2 (en) 2008-03-25
NO331457B1 (no) 2012-01-09
AU2003293310B2 (en) 2010-04-01
RU2005113165A (ru) 2005-10-10
CY1112174T1 (el) 2015-12-09
DK2042504T3 (da) 2011-09-19
US20090270388A1 (en) 2009-10-29
MY140756A (en) 2010-01-15
KR20050067404A (ko) 2005-07-01
HK1084393A1 (zh) 2006-07-28
ATE511510T1 (de) 2011-06-15
BR0314830A (pt) 2005-08-16
SI2042504T1 (sl) 2011-10-28
IL166855A (en) 2014-05-28
ECSP055768A (es) 2005-08-11
HRP20050375B1 (hr) 2014-03-14
NZ539062A (en) 2007-05-31
CA2499134C (en) 2011-12-20
JP4790266B2 (ja) 2011-10-12
MXPA05001808A (es) 2005-08-16
DK1549652T3 (da) 2009-02-23
EP1549652A1 (en) 2005-07-06
CA2499134A1 (en) 2004-04-08
PE20050089A1 (es) 2005-04-20
JP2006508063A (ja) 2006-03-09
US20060128732A1 (en) 2006-06-15
ZA200503306B (en) 2006-07-26
RU2326881C9 (ru) 2009-04-10
AR041426A1 (es) 2005-05-18
EP2042504A1 (en) 2009-04-01
PL226562B1 (pl) 2017-08-31
CN1688582A (zh) 2005-10-26
EP1549652B1 (en) 2008-10-22
BRPI0314830B8 (pt) 2021-05-25
MA27483A1 (fr) 2005-08-01
EP2042504B1 (en) 2011-06-01
BRPI0314830B1 (pt) 2018-03-27
ES2367141T3 (es) 2011-10-28

Similar Documents

Publication Publication Date Title
ECSP11005768A (es) Derivados de azol-pirimidina condensados
ES2194501T3 (es) Derivados de amidinas, su preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
UY26258A1 (es) Derivados de 8-fenil-6,9-dihidro-[1,2,4] triazolo [3,4-i] purin-5-ona.
UY26511A1 (es) Bases de mannich indólicas, procedimientos para su preparación, medicamentos que contienen estos compuestos y su uso para la preparación de medicamentos
CY1106468T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
UY27381A1 (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas y su uso
ES2144192T3 (es) Nuevos derivados de 1-fenil-2-dimetil-amino-metil-ciclohexan-1-ol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
HN2002000300A (es) Nuevos derivados de piperazina
DK1307227T3 (da) Farmaceutiske sammensætninger
ES2178055T3 (es) Derivados aminicos substituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
HN2001000235A (es) Derivados puentes de piperazina
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
DK1150704T3 (da) Melagatran til behandling af betændelse
ATE253359T1 (de) Antithrombotische mittel
ATE402158T1 (de) Flavonoid-derivat
PT880520E (pt) Derivados da benzo¬c|quinolizina sua preparacao e uso como inibidores da 5-alfa-reductase
AR028590A1 (es) Derivados de sulfonamidas; composiciones farmaceuticas y articulos de fabricacion que incluyen dichos derivados; procedimiento para prepararlos, procedimiento para potenciar las funciones de los receptores lutamato utilizando dichos derivados, respectivamente tratar pacientes afectados de depresion,
DE69828522D1 (de) Antithrombotische mittel
DK1267892T3 (da) Anvendelse af CDP-cholin til behandling af alkoholabstinenssyndrom
UY27372A1 (es) Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados
PT989994E (pt) Derivados de estreptograminas, a sua preparacao e as composicoes que os contem
UY26507A1 (es) Bases de mannich de 1-naftol y 2-naftol sustituidos, procedimiento para su preparación, medicamentos que contienen estos compuestos, así como el uso de estos compuestos para la preparación de medicamentos